LifeCord has a strong intellectual property (IP) portfolio, including 52 patent families pending worldwide and 21 issued or allowed patents. This IP position ensures market exclusivity and gives LifeCord a significant competitive edge.
You can learn more about the company below.
LifeCord is pioneering innovative solutions for mitral chordal repair, addressing mitral regurgitation, which affects approximately 2% of the global population. Our flagship product is a breakthrough leaflet-preserving device that avoids puncturing the leaflet and enables future interventions, aiming to disrupt the market with a safer, superior, and primary solution for degenerative mitral regurgitation (DMR) patients. The device offers a minimally invasive transfemoral alternative to open-heart surgery, meeting a critical need as a first-line therapy option. LifeCord is poised to be an important player in the rapidly growing market for mitral valve interventions which is already exceeding $2 billion.
Backed by a strong intellectual property portfolio, LifeCord secures a competitive advantage, protecting the core elements of its technology and reinforcing its market exclusivity.
Keep reading at calcalistech.com.
LifeCord CEO Yaron David is a Technion alumnus.
